Archive for the ‘Pain Relief’ Category

https://www.sciencedaily.com/releases/2018/02/180215153923.htm

This paper cites the need for more, controlled research into medical cannabis uses and no one would argue that, but their usage and conclusions are questionable.  First, for pain relief, cannabis has an interesting property.  It only reduces pain slightly, but renders the patient not caring about it, thus making the pain more tolerable.  Unrealistic expectations also can interfere with analgesic properties.  Given cannabis’ sedative effects, it is often best used at night, when opiates would wear off, waking the patient, while cannabis lasts the night through.  Cannabis should be administered orally for a longer, time-release, effect, with 1-3 hours (2 typ) allowed before effects begin.

Further, some of the pain relief may be through defacto hypnosis, since cannabis can be considered a hypnotic drug, and therefore be heavily modulated by the patient’s mindset.  Inexperienced patients may feel anxiety, thereby rendering cannabis less effective for pain and sleep.

It is important for the prescribing physician to determine the patient’s familiarity and experience with cannabis before prescribing, as such patients often know subjectively how well it works for them.  Novice patients need be counseled on what cannabis does and does not do, with sufficient disclaimers so as to not give unrealistic expectations.  “This may make it easier for you to sleep through the pain and you might experience a bit of dizziness if you get up at night”, would be appropriate advice.  Note that pain is not mentioned.  “If you wake and still notice pain, you may find it diminishing and becoming more tolerable as you drift off to sleep” is another bit of good advice.  Perhaps all the analgesic properties are due to self hypnosis, induced by the drug, so much more research is needed, but the subjective insistence as to its effectiveness should not be dismissed.

AuntieBS

 

Advertisements

https://www.sciencedaily.com/releases/2018/02/180207090111.htm

Just guessing, I would assume that heroin addicts would augment their highs with strong cannabis doses, thereby using less opiate (stretching it for lower cost, longer availability) and thereby having fewer overdoses.  Medical cannabis is more often sold in stronger concentrates and infused candy for a more time-released effect, than is typically available in legal recreational cannabis markets.

Cannabis users that concurrently use alcohol, generally smoke less cannabis and drink less alcohol, than either alone.  Why would not the same relationship occur between those using cannabis and heroin, concurrently?

AuntieBS

Survey: Many Medical Cannabis Patients Cease Using Opioids

Thursday, 16 November 2017

Medical Marijuana Less OpioidsChicago, IL: More than two out of three medical marijuana patients substitute cannabis in place of opioids, according to survey data compiled by Aclara Research, a Chicago-based consulting firm.

Sixty-seven percent of respondents reported that they ceased their opioid use after initiating cannabis therapy. Twenty-nine percent of respondents said that cannabis allowed them to decrease their use of opioids.

The findings are similar to those of prior surveys concluding that patients who use cannabis therapeutically typically reduce or cease their use of opioids and other prescription pharmaceuticals.

According to an October 21 academic paper published on SSRN.com, the enactment of medical marijuana access laws is associated with a $2.47 decrease in per person prescribed opioid spending among those between the ages of 18 and 39. Previous studies – such as those herehere, and here – have drawn similar conclusions.

On November 1, members of President Trump’s opioid commission rejected the notion that cannabis access is associated with reduced rates of opioid abuse and mortality. By contrast, the US National Institute on Drug Abuse acknowledges that available studies “cumulatively suggest that medical marijuana products may have a role in reducing the use of opioids.”

For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org.

A pre-clinical study reports that the use of the positive allosteric modulator GAT211 enhances the effect of pain-relief chemicals produced by the body in response to stress or injury. The research is a promising step forward in the search for pain relief methods without the addictive side effects of opioids.

Source: Pre-clinical study suggests path toward non-addictive painkillers: Researchers use a compound with a novel mechanism to treat pain in mice without tolerance or physical dependence — ScienceDaily

More than 130,000 Anterior Cruciate Ligament (ACL) surgeries take place each year with the majority of patients not requiring pain medication after three months post-operatively. However, researchers have found that those patients who were filling opioid prescriptions prior to surgery were 10 times more likely to be filling prescriptions five months after surgery.

Source: Patients taking opioids prior to ACL surgery more likely to be on pain medications longer — ScienceDaily

 

That brilliance could be read, “Patients who have lower thresholds of pain and/or more extensive ACL damage,  are more likely to use opiates longer”.  Well, DUH!  Where is the causality?  Are people in greater pain more likely to take opiates before surgery, as well as for longer after?  This may be the causal factor vs the implication that if we withhold pain relief until after surgery, it will toughen people to do without pain relief quicker.  Puh-lease.  They are not determining the causal factor here.  Bad study.

AuntieBS

NORML’s mission is to move public opinion sufficiently to legalize the responsible use of marijuana by adults, and to serve as an advocate for consumers to assure they have access to high quality marijuana that is safe, convenient and affordable.

Source: NORML.org – Working to Reform Marijuana Laws – NORML.org – Working to Reform Marijuana Laws

Medical Marijuana Legalization Associated With Fewer Opioid-Related Hospitalizations

Medical Marijuana - Fewer Opioid-Related HospitalizationsSan Diego, CA: The enactment of statewide legislation permitting medical cannabis access by qualified patients is associated with a reduction in opioid-related hospitalization, according to data published online ahead of print in the journal Drug and Alcohol Dependence.

A researcher from the University of California at San Diego assessed the association between medical cannabis laws and hospitalizations related to opioid pain relievers. The author reported both immediate and longer-term reductions in opioid-related hospitalization following changes in law.

“This study demonstrated significant reductions on OPR- (opioid pain reliever) related hospitalizations associated with the implementation of medical marijuana policies. … We found reductions in OPR-related hospitalizations immediately after the year of policy implementation as well as delayed reductions in the third post-policy year.”

The author also dismissed contentions that liberalized marijuana laws were associated with any subsequent increase in marijuana-related hospital admissions, concluding: “While the interpretation of the results should remain cautious, this study suggested that medical marijuana policies were not associated with marijuana-related hospitalizations. Instead, the policies were unintendedly associated with substantial reductions in OPR related hospitalizations.”

The findings are consistent with those of other studies reporting that medical cannabis legalization is associated with lower rates of opioid abuse, mortality, and prescription drug spending.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever,” appears in Drug and Alcohol Dependence.

Israeli Cabinet Endorses Marijuana Decriminalization Plan

Israeli Marijuana Decriminalization PlanJerusalem, Israel: Israeli lawmakers have signed off on legislation decriminalizing offenses involving the possession of personal use quantities of marijuana.

Under the new policy, first and second time possession offenders will face a fine, but no criminal penalties.

“The Cabinet approval is an important step on the way to implementing the new policy that will put emphasis on explaining and treating rather than on criminal enforcement,” explained Israeli Public Security Minister Gilad Erdan.

The medical production and distribution of cannabis for medical purposes is already legally permitted in Israel as part of a program governed by the Ministry of Health. About 25,000 Israelis receive medical marijuana as part of this program.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org.

Study: CBD-Dominant Cannabis Extracts Reduce Seizure Frequency

CBD Cannabis Extracts Reduce SeizuresFalmouth, ME: The administration of whole-plant cannabis extracts rich in the cannabinoid cannabidol (CBD) is associated with reduced seizure frequency in patients with refractory epilepsy, according to data published online ahead of print in the journal Epilepsy & Behavior.

Researchers performed a retrospective chart review of the clinical records of 272 patients who were taking whole-plant CBD extracts.

Eighty-six percent of those treated observed some clinical benefit (a reduction in seizure frequency) while ten percent experienced a complete clinical response. The remaining patients were either not responsive to treatment or reported an exacerbation of seizures during therapy.

Beneficial side effects, such as improved mood, better sleep quality, and increased appetite were reported.

“The cannabinoids’ novel mechanisms of action are an attractive consideration for possible seizure control,” authors concluded. “In patients with refractory epilepsy that have a low likelihood of responding to a subsequent AED (anti-epileptic drug), a trial of artisanal cannabis formulas may be indicated.”

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “The current status of artisanal cannabis for the treatment of epilepsy in the United States,” appears in Epilepsy & Behavior. Additional data regarding the efficacy of cannabinoids as anticonvulsants appears in NORML’s library.

Pennsylvania: Auditor General Says State Lawmakers Should Regulate The Marijuana Market

Pennsylvania Should Regulate MarijuanaHarrisburg, PA: Pennsylvania’s auditor general on Monday publicly advocated for the legalization and taxation of retail marijuana sales, arguing that such a policy would bring new jobs and tax revenue to the state.

Speaking at a news conference at the state capitol, Auditor General Eugene DePasquale said: “The regulation and taxation of the marijuana train has rumbled out of the station, and it is time to add a stop in the Commonwealth of Pennsylvania. I make this recommendation because it is a more sane policy to deal with a critical issue facing the state. Other states are already taking advantage of the opportunity for massive job creation and savings from reduced arrests and criminal prosecutions. In addition, it would generate hundreds of millions of dollars each year that could help tackle Pennsylvania’s budget problems.”

However, Gov. Tom Wolf said that state lawmakers should not go forward with regulating the adult use marijuana market at this time. Instead, he expressed support for decriminalizing the possession and personal use of the plant.

For more information, please contact Justin Strekal, NORML Political Director, at (202) 483-5500 or visit: http://www.phillynorml.org/.

NORML and the NORML Foundation: 1100 H Street NW, Suite 830, Washington DC, 20005
Tel: (202) 483-5500 • Fax: (202) 483-0057 • Email: norml@norml.org

Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to new research.

Source: Given the choice, patients will reach for cannabis over prescribed opioids — ScienceDaily